STAT7h
Pharmalittle: We’re reading about possible HIV prevention cuts, FDA warning an African drugmaker, and more
The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...
Fierce Healthcare2d
HHS may cut HIV prevention efforts at the CDC. Advocates fear changes will spike infections
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...
Trump Trade: President to sign EO on DOE, weighing Chevron license extension
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and ...
HIV Drug Makers Get Spooked by Possible Trump Cut, but Impact Looks Manageable
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Healio6d
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Business Wire9d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and ...